Michael D. Laufert

Consumer Services

Health Technology

Profile

Mr. Laufert was previously employed as a Principal by GCP Fund III Corp., a Principal by Guilford Pharmaceuticals, Inc., and a Principal by Pfizer Inc. Mr. Laufert received his undergraduate degree from Mount St. Mary's College, a graduate degree from Georgetown University, and an MBA from Johns Hopkins University.

Former positions of Michael D. Laufert

Companies	Position	End
Guilford Pharmaceuticals, Inc. Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury	Corporate Officer/Principal	-
GCP Fund III Corp.	Corporate Officer/Principal	-
PFIZER, INC.	Corporate Officer/Principal	-

See the detail of Michael D. Laufert's experience

Training of Michael D. Laufert

The Johns Hopkins University	Masters Business Admin
Mount Saint Mary's University	Undergraduate Degree
Georgetown University	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael D. Laufert's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PFIZER, INC.	Health Technology

Private companies	2
Guilford Pharmaceuticals, Inc. Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury	Health Technology
GCP Fund III Corp.